SAN FRANSICO 30 Nov (Online): An experimental Alzheimer’s drug from Eisai (4523.T) and Biogen (BIIB.O) slowed cognitive decline in a closely watched trial but may carry a risk of serious side effects for certain patients, according to detailed data presented on Tuesday. The drug, lecanemab, […]
